Strategic License Agreements - Additional Information (Details)	1 Months Ended		3 Months Ended			9 Months Ended
	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($) € / shares $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 174,000	$ 1,399,000		$ 2,161,000	$ 15,095,000
Current deferred revenue			505,000			505,000		$ 2,359,000
Contract liabilities			2,679,000	0		2,679,000	0	$ 3,576,000
Contract assets			0	0		$ 0	0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date						2021-03
Non refundable payment received					$ 21,500,000
Percentage of payment for cost incurred in PIP trial					50.00%
Additional upfront payment to be received					$ 113,400,000
Rate of revenue share					25.00%
Reimbursement	$ 3,000,000.0
Upfront payment					$ 21,500,000
Modified transaction price	25,100,000
Estimated amount incurred	$ 3,600,000
Allocation price net					12,000,000.0
Total deferred revenue			2,700,000	6,400,000		$ 2,700,000	6,400,000
Current deferred revenue			500,000	4,800,000		500,000	4,800,000
Immedica Pharma AB | PEACE Trial and BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price					9,600,000
Revenue recognized			$ 200,000	1,400,000		$ 2,200,000	3,100,000
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price					$ 3,500,000
Immedica Pharma AB | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 12,000,000.0		$ 0			$ 12,000,000.0
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial					50.00%
Costs incurred in performing PIP the trial					$ 1,800,000
Milestone payments exchange rate | € / shares					1.00
Immedica Pharma AB | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments exchange rate | $ / shares					0.98